Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2016

Study Completion Date

March 31, 2017

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Docetaxel, Cisplatin, 5-FU and Cetuximab

"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"

Trial Locations (4)

Unknown

Department of Clinical Oncology, Queen Mary Hospital(QMH), Hong Kong, Hong Kong

Department of Clinical Oncology, Queen Mary Hospital, Hong Kong

Department of Clinical Oncology, Tuen Mun Hospital (TMH), Hong Kong, Hong Kong

Department of Oncology, Princess Margaret Hospital, Hong Kong

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The University of Hong Kong

OTHER

collaborator

Sanofi

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Roche Pharma AG

INDUSTRY

lead

Hong Kong Nasopharyngeal Cancer Study Group Limited

OTHER

NCT01326559 - Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) | Biotech Hunter | Biotech Hunter